Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment

References 

1. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation. 1998;97:1453–1460
   • MEDLINE
2. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001;285:2486–2497.
3. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch. Intern. Med. 2001;161:1413–1419
   • MEDLINE
   • CrossRef
4. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am. J. Cardiol. 1998;81(Suppl 1):26B–31B
   • Abstract
   • Full Text
   • Full-Text PDF (63 KB)
   • CrossRef
5. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G. Non-high-density lipoprotein Cholesterol levels predict five-year outcome in the bypass angioplasty revascularization investigation (BARI). Circulation. 2002;106:2537–2542
   • CrossRef
6. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ. Non-HDL Cholesterol as a predictor of cardiovascular disease in type 2 diabetes: The Strong Heart Study. Diabetes Care. 2003;26:16–23
   • MEDLINE
   • CrossRef
7. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis AC. Treatment with atorvastatin to the national cholesterol educational program goals versus usual care in secondary coronary heart disease prevention: The Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Curr. Med. Res. Opin. 2002;18:220–228
   • MEDLINE
   • CrossRef